Can HRT be taken for many years safely?

Whether long-term HRT is appropriate depends on individual health history, timing of initiation, and ongoing clinical reassessment — factors that cannot be evaluated through website content alone. For many women, extended use continues to offer benefits for symptoms, bone health, sleep, mood, and quality of life when properly monitored by a prescriber.

How long is considered appropriate?

According to current NAMS guidelines, starting HRT within approximately 10 years of menopause or before age 60 represents the period with the most favorable benefit-risk profile. Per published clinical guidelines, there is no universal mandatory time limit for HRT use; duration should be determined through regular clinical reassessment based on each patient's evolving health status.

Breast cancer considerations

• Estrogen-only therapy: According to the WHI long-term follow-up data, estrogen-only therapy (used after hysterectomy) has not been shown to increase breast cancer risk and was associated with a slight reduction in incidence in some analyses.
• Estrogen with progesterone: Per published clinical guidelines, combined estrogen-progestogen therapy may be associated with a small increase in breast cancer risk after 5 or more years of use; the absolute increase in risk is modest and comparable in magnitude to that associated with other lifestyle factors.

According to current NAMS guidelines, micronized progesterone and certain progestogen formulations appear to have a more favorable metabolic profile compared to older synthetic progestins, though the clinical significance of these differences continues to be evaluated in ongoing research.

Both FDA-approved products (such as estradiol and micronized progesterone) and compounded preparations may contain bioidentical hormones. The term does not indicate superiority of one category over another.

Heart and stroke considerations

According to the WHI long-term follow-up data, initiating HRT early (before age 60 or within 10 years of menopause onset) has been associated with a more favorable cardiovascular risk profile, while initiation at an older age or further from menopause has been linked to increased cardiovascular and thromboembolic risk. Per published clinical guidelines, transdermal estrogen (patch, gel, or spray) is associated with lower thromboembolic risk compared to oral formulations, which may be relevant for women requiring long-term use.

Bone, brain, and symptom considerations

• Bone: According to current NAMS guidelines, HRT is effective at reducing bone loss and fracture risk during the period of active use.
• Brain: Per published clinical guidelines, early initiation of HRT has been associated with improvements in certain cognitive symptoms; long-term effects on brain health remain an active area of research.
• Symptoms: Per FDA-approved prescribing information, HRT is indicated for the treatment of moderate to severe vasomotor symptoms, including hot flashes and night sweats, and genitourinary symptoms associated with menopause.

Factors associated with safer long-term use

• Using the lowest effective dose that adequately manages symptoms, per current clinical practice.
• Preferring transdermal estrogen to reduce thromboembolic risk, per published clinical guidelines.
• Using body-identical progesterone (FDA-approved or compounded) when a uterus is present, as directed by a prescriber.
• Annual clinical reviews to assess breast health, blood pressure, and ongoing dose appropriateness.

Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

Whether HRT is appropriate depends on individual health factors. A prescriber should determine the best approach based on a patient's complete medical history.